CN101243053B - N-酰基氨基酸衍生物、其制备方法、药物组合物及其作为抗变应性、抗炎和降血脂药物的用途 - Google Patents

N-酰基氨基酸衍生物、其制备方法、药物组合物及其作为抗变应性、抗炎和降血脂药物的用途 Download PDF

Info

Publication number
CN101243053B
CN101243053B CN2006800296822A CN200680029682A CN101243053B CN 101243053 B CN101243053 B CN 101243053B CN 2006800296822 A CN2006800296822 A CN 2006800296822A CN 200680029682 A CN200680029682 A CN 200680029682A CN 101243053 B CN101243053 B CN 101243053B
Authority
CN
China
Prior art keywords
compound
amino acid
salt
general formula
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800296822A
Other languages
English (en)
Chinese (zh)
Other versions
CN101243053A (zh
Inventor
弗拉迪米尔·叶夫根尼耶维奇·涅博利辛
塔特亚娜·亚历山多夫娜·克罗莫娃
佳丽娜·亚历山多夫娜·哲尔图克西娜
维莱塔·列奥尼多夫娜·科瓦列娃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Domestic Listed Pharmaceutical Co
Original Assignee
Domestic Listed Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domestic Listed Pharmaceutical Co filed Critical Domestic Listed Pharmaceutical Co
Publication of CN101243053A publication Critical patent/CN101243053A/zh
Application granted granted Critical
Publication of CN101243053B publication Critical patent/CN101243053B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2006800296822A 2005-06-15 2006-06-15 N-酰基氨基酸衍生物、其制备方法、药物组合物及其作为抗变应性、抗炎和降血脂药物的用途 Expired - Fee Related CN101243053B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2005118635 2005-06-15
RU2005118635/04A RU2335495C2 (ru) 2005-06-15 2005-06-15 N-ацильные производные аминокислот, их фармацевтически приемлевые соли, фармацевтическая композиция и применение в качестве гиполипидемических средств
PCT/RU2006/000311 WO2006135280A1 (en) 2005-06-15 2006-06-15 N-acylic aminoacid derivatives. method for the production thereof, pharmacological composition and the use in the form of anti-allergic, anti-inflammatory and hypolipidemic agents

Publications (2)

Publication Number Publication Date
CN101243053A CN101243053A (zh) 2008-08-13
CN101243053B true CN101243053B (zh) 2012-08-08

Family

ID=37502176

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800296822A Expired - Fee Related CN101243053B (zh) 2005-06-15 2006-06-15 N-酰基氨基酸衍生物、其制备方法、药物组合物及其作为抗变应性、抗炎和降血脂药物的用途

Country Status (10)

Country Link
US (2) US8940780B2 (enExample)
EP (1) EP1905763B1 (enExample)
JP (2) JP2008543830A (enExample)
KR (1) KR101402855B1 (enExample)
CN (1) CN101243053B (enExample)
CA (1) CA2612324C (enExample)
EA (1) EA013057B1 (enExample)
RU (1) RU2335495C2 (enExample)
UA (1) UA94586C2 (enExample)
WO (1) WO2006135280A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2373934C1 (ru) * 2008-03-19 2009-11-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
EP2351848B1 (en) * 2008-10-29 2018-02-28 Kaneka Corporation Method for producing l-amino acid
WO2010064958A2 (ru) * 2008-12-01 2010-06-10 Закрытое Акционерное Общество "Мастерклон" Ингибиторы протеинкиназы с, обладающие противовоспалительным, противоаллергическим и противоастматическим действием
UA115431C2 (uk) * 2011-10-11 2017-11-10 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Застосування глутарилгістаміну для лікування захворювань дихальних шляхів
CN102757388B (zh) * 2012-07-04 2015-05-20 四川百利药业有限责任公司 一种高纯度英加韦林的制备方法
RU2518314C2 (ru) * 2012-08-30 2014-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
CN117965408A (zh) 2013-03-15 2024-05-03 模块遗传学公司 酰基氨基酸的产生
RU2665688C2 (ru) * 2013-04-12 2018-09-04 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
CN103288741B (zh) * 2013-05-24 2015-09-30 华南农业大学 一种组胺半抗原、人工抗原、抗体及其制备方法与应用
WO2015021064A1 (en) * 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
RU2628800C2 (ru) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
CN104119277B (zh) * 2014-07-16 2016-08-17 华南农业大学 一种直接针对组胺的半抗原、人工抗原、抗体及其制备方法与应用
CN104230833B (zh) * 2014-10-07 2016-01-20 张远强 含腈基的四氮唑乙酸类化合物、其制备方法及用途
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
RU2665638C1 (ru) * 2017-05-24 2018-09-03 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
CN110031583B (zh) * 2018-12-29 2022-01-18 浙江工业大学 分离测定n-琥珀酰色氨酸对映异构体的液相色谱方法
CA3139470C (en) * 2019-05-24 2024-10-15 Stemdr Inc. A composition enabling the prevention or treatment of asthma, rhinitis, or conjunctivitis, comprising N-acylamine acid as the active ingredient.
EP3977990A4 (en) * 2019-05-24 2023-06-14 Stemdr Inc. COMPOSITION FOR THE PREVENTION OR TREATMENT OF ASTHMA, RHINITIS OR CONJUNCTIVITIS WITH N-ACYL AMINO ACID AS THE ACTIVE INGREDIENT

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1020179A2 (en) * 1997-07-04 2000-07-19 Vladimir Evgenievich Nebolsin Peptide derivatives or pharmaceutically acceptable salts thereof, method for producing the same, use of said derivatives and pharmaceutical composition
WO2003072124A1 (en) * 2002-02-28 2003-09-04 Vladimir Evgenievich Nebolsin Induction method for cell differentiation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004690A1 (en) 1991-09-09 1993-03-18 Peptide Technology Limited Method for the treatment of the complications and pathology of diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1020179A2 (en) * 1997-07-04 2000-07-19 Vladimir Evgenievich Nebolsin Peptide derivatives or pharmaceutically acceptable salts thereof, method for producing the same, use of said derivatives and pharmaceutical composition
WO2003072124A1 (en) * 2002-02-28 2003-09-04 Vladimir Evgenievich Nebolsin Induction method for cell differentiation

Also Published As

Publication number Publication date
RU2005118635A (ru) 2006-11-20
KR101402855B1 (ko) 2014-06-03
EP1905763A4 (en) 2008-08-27
CN101243053A (zh) 2008-08-13
JP2008543830A (ja) 2008-12-04
US8940780B2 (en) 2015-01-27
UA94586C2 (ru) 2011-05-25
EP1905763B1 (en) 2019-05-08
EP1905763A1 (en) 2008-04-02
US20080319040A1 (en) 2008-12-25
EA200800054A1 (ru) 2008-06-30
JP5836995B2 (ja) 2015-12-24
WO2006135280A1 (en) 2006-12-21
US8318950B2 (en) 2012-11-27
JP2013151551A (ja) 2013-08-08
CA2612324A1 (en) 2006-12-21
US20100267962A1 (en) 2010-10-21
KR20080039872A (ko) 2008-05-07
CA2612324C (en) 2014-12-30
EA013057B1 (ru) 2010-02-26
RU2335495C2 (ru) 2008-10-10

Similar Documents

Publication Publication Date Title
JP5836995B2 (ja) アミノ酸のｎ−アシル誘導体、その製法、薬理組成物および抗−アレルギー性、抗−炎症性および抗−脂血性薬剤としてのその使用
US20070203209A1 (en) Useful indole compounds
RU2552929C1 (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
US6303617B1 (en) Serotonin-like 9-substituted hypoxanthine and methods of use
JP2003500403A (ja) ｐ３８キナーゼのインヒビターとしてのインドール型誘導体
JPH10168062A (ja) ３−ヒドロキシピリジン−２−カルボキサミドエステル、その製造および薬剤としてのその使用
WO2021114864A1 (zh) 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途
EP4306517A1 (en) Triazole derivative, preparation method therefor, and application thereof
JP2001506997A (ja) ホスホチロシン認識ユニットを有する蛋白質の修飾物質
CA2576727C (fr) Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
US7795295B2 (en) Small molecule inhibition of PDZ-domain interaction
CN1330667C (zh) 分离肠胆固醇结合蛋白的方法
CN110551048A (zh) 一类sirt2抑制剂、其制备方法及用途
RU2406727C2 (ru) Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств
CN100368397C (zh) D-脯氨酸的前药
RU2378284C2 (ru) Способы получения n-ацильных производных аминокислот (варианты)
HK1118816A (en) N-acylic aminoacid derivatives. method for the production thereof, pharmacological composition and the use in the form of anti-allergic, anti-inflammatory and hypolipidemic agents
Tsiamantas et al. Solid phase synthesis of oligoethylene glycol-functionalized quinolinecarboxamide foldamers with enhanced solubility properties
RU2802463C1 (ru) Гидроксамовые кислоты, производные 4-аминохиназолина, обладающие противоопухолевой активностью
RU2832307C2 (ru) Производное триазола, способ его получения и его применение
JP2005053780A (ja) 核内レセプタースーパーファミリーの新規リガンド、その製法及び用途
JPS6253963A (ja) 肝疾患治療剤
Code Ivacaftor Properties
JPH08277258A (ja) 高度不飽和脂肪酸残基を有するアニリン誘導体およびａｃａｔ阻害剤
HK1082509B (en) Method for isolating an intestinal cholesterol binding protein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120808

CF01 Termination of patent right due to non-payment of annual fee